Searched for
DIVIS Q2
Sunil Singhania-backed Abakkus Small Cap Fund adds 3 new stocks, increases stake in HDFC Bank, SBI and 49 othersSunil Singhania's Abakkus Small Cap Fund added three new stocks in May, including Tanla Platforms and Intellect Design Arena. The fund also...- Divi's Laboratories Q4 Results: Cons PAT grows 13% YoY to Rs 751 crore, revenue up 10%; Rs 30 per share dividend announcedDivi's Laboratories Q4 Results: Divi's Laboratories announced strong financial results for the March quarter. Net profit rose 13% to Rs 751...
- Divi’s Lab shares up 3% after Q4 PAT surges 26% YoY. Should you invest?Divi's Laboratories reported a strong Q4FY25, with a 26% YoY increase in net profit to Rs 667 crore and a 12.26% rise in revenue to Rs 2,53...
- Divi's Labs shares up 6% after Q3 PAT jumps 64% YoY. Should you buy, sell, or hold?Divi's Labs surged 6% after reporting a 64% YoY profit jump in Q3FY25. Revenue rose 25% YoY to Rs 2,319 crore. Goldman Sachs stays Neutral ...
- Divi’s Laboratories Q2 Results: Company posts 47% jump in net profit in Q2FY25Divi's Laboratories witnessed a 46.6% surge in profit, reaching Rs. 510 crores in Q2FY25, fueled by robust growth in their custom synthesis...
- Divi's Laboratories Q2 Results: PAT jumps 46% YoY to Rs 510 crore on forex gainDivi's Laboratories Q2 Results: The company reported a 22.5% year-on-year revenue increase in Q2, reaching Rs 2,338 crore, up from Rs 1,909...
- Divi's Laboratories Q1 Results: Cons PAT jumps 21% YoY to Rs 430 crore, misses estimatesDivi's Laboratories reported a consolidated net profit of Rs 430 crore for the quarter ended June 30, 2024, which was up by 21% over Rs 356...
- Hot Stocks: Brokerages on Varun Beverages, Divi’s Laboratories, Nykaa and Bharat ForgeCLSA downgraded Bharat Forge to sell and Morgan Stanley maintained an overweight rating on Nykaa.
- Divi's Lab Q2 Results: Profit falls 29% YoY to Rs 348 crore, misses estimatesRevenue from operations rose 3% year-on-year (YoY) to Rs 1,909 crore in the July-September period. It was Rs 1,855 crore in the correspondi...
- Earnings Tracker: 5 Nifty50 companies can post over 40% profit fall in Q3As for Hindalco, most brokerages expect the profit decline to by 30-40%. MOSL pegs reported PAT for the company in Q3 at Rs 2,100 crore, do...
- Divi's Labs shares fall for 5th day, tank over 4%The company's total revenue dipped 3.6% YoY to Rs 1,935 crore for the quarter ended September 30 as against a consolidated total income of ...
- Divi's Labs Q2 Results: Profit falls 19% YoY to Rs 494 croreThe Hyderabad-based drugmaker disappointed the Street which was estimating a profit of Rs 630 crore.
- Divi's Labs tumbles more than 8% after Q2 numbers; here is what analysts have to sayShares of drug firm Divi's Labs fell more than 8% as analysts forecast rising near-term pressures amid logistical issues, higher raw materi...
- Buy Divi's Laboratories, target price Rs 4205: ICICI DirectDivi's Laboratories Ltd., incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 95871.32 Crore) operating in Pha...
- Divi’s Labs hits all-time high after robust Q2 resultsA recent entrant to the Nifty pack, Divi’s Labs is up 82 per cent year-to-date, and has almost doubled over the last one year.
- Divi's Labs Q2 results: Net profit jumps 46% YoY to Rs 520 croreFor the current quarter, Divi’s Labs witnessed a forex loss of Rs 16 crore against a gain of Rs 13 crore.
- Divi’s Labs Q2 preview: Firm to maintain momentum, PAT to grow in double digitsDivi’s Labs has been one of the best performing pharma companies this year, as far as market returns are concerned.
- Divi's Lab Q2 profit dips 12% to Rs 357 croreRevenue from operations rose to Rs 1,445.57 crore.
- Buy Divi's Laboratories, target Rs 1,600: Axis CapitalBuy Divi's Laboratories Ltd. at a price target of Rs 1600.
- Buy Divi's Laboratories, target Rs 1,275: SharekhanBuy Divi's Laboratories Ltd. at a price target of Rs 1275.0 .
Load More
